Join us live in Chicago or virtually to discover the latest breakthroughs in oncology and hematology! Expert faculty will facilitate exciting satellite symposia, where you will interact with other professionals and receive practical guidance on a wide range of malignancies.
The best part? You do not need to be an ASCO registrant to join our events! Claim free CME/CE credits and receive complimentary slides to support your presentation needs.
Dates May 30th - May 31st
Time Varies per Event
Timezone Converter ›
Location Hilton Chicago
720 S. Michigan Ave.
Chicago, IL 60605
Bus RouteShuttle Bus Route 10:
From McCormick Place:
North - Gate 26
Attend in-person or via virtual simulcast.
May
302025
6:30 PM - 8:30 PM Central Time (CT)
In-person
7:00 PM - 8:30 PM Central Time (CT)
Virtual
May
302025
6:30 PM - 8:30 PM Central Time (CT)
In-person
7:00 PM - 8:30 PM Central Time (CT)
Virtual
May
302025
6:30 PM - 8:30 PM Central Time (CT)
In-person
7:00 PM - 8:30 PM Central Time (CT)
Virtual
May
302025
6:30 PM - 8:30 PM Central Time (CT)
In-person
7:00 PM - 8:30 PM Central Time (CT)
Virtual
May
302025
6:30 PM - 8:30 PM Central Time (CT)
In-person
7:00 PM - 8:30 PM Central Time (CT)
Virtual
May
312025
6:30 AM - 7:30 AM Central Time (CT)
Virtual
May
312025
6:30 PM - 8:30 PM Central Time (CT)
In-person
7:00 PM - 8:30 PM Central Time (CT)
Virtual
May
312025
6:30 PM - 8:30 PM Central Time (CT)
In-person
7:00 PM - 8:30 PM Central Time (CT)
Virtual
May
312025
6:30 PM - 8:30 PM Central Time (CT)
In-person
7:00 PM - 8:30 PM Central Time (CT)
Virtual
May
312025
6:30 PM - 8:30 PM Central Time (CT)
In-person
7:00 PM - 8:30 PM Central Time (CT)
Virtual
May
312025
6:30 PM - 8:30 PM Central Time (CT)
In-person
7:00 PM - 8:30 PM Central Time (CT)
Virtual
June
012025
6:30 AM - 7:30 AM Central Time (CT)
Virtual
Expert Perspectives on Updates and Advances in Individualizing CLL/SLL Therapy Across the Disease Course
Physicians: maximum of 1.50 AMA PRA Category 1 Credits™
Registered Nurses: 1.50 Nursing contact hours
Physician Assistants: maximum of 1.50 AAPA Category 1 CME credits
Pharmacists: 1.50 contact hours (0.15 CEUs)
Physicians ABIM MOC: maximum of 1.50 Medical Knowledge MOC points
Mastering the Evolving Treatment Paradigm in SCLC: Expert Case Discussions to Aid Integration of Immunotherapy and Novel Targeted Therapies
Physicians: maximum of 1.50 AMA PRA Category 1 Credits™
Physicians ABIM MOC: maximum of 1.50 Medical Knowledge MOC points
Overcoming Endocrine Resistance in HR+/HER2- MBC: Tailoring Treatment for Patients With ESR1- and PI3K/AKT/PTEN-Altered Disease Post-ET Progression
Nurse Practitioners/Nurses: 1.50 Nursing contact hours
Pharmacists: 1.50 contact hours (0.15 CEUs)
Physician Assistants/Physician Associates: 1.50 AAPA Category 1 CME credits
Physicians: maximum of 1.50 AMA PRA Category 1 Credits™
Physicians ABIM MOC: maximum of 1.50 Medical Knowledge MOC points
New Treatments on the Horizon: Cancer Conversations on Novel Mechanisms and Emerging Treatment Options in mCRPC
Physicians: maximum of 1.50 AMA PRA Category 1 Credits™
Challenging Treatment Paradigms in HER2-Low and HER2-Ultralow MBC: Experts Examine The Evidence to Guide Individualized Clinical Decisions
Physicians: maximum of 1.50 AMA PRA Category 1 Credit™
Physicians ABIM MOC: maximum of 1.50 Medical Knowledge MOC points
Novel Therapeutic Approaches and Personalized Strategies for Managing Anemia in LR-MDS
Physicians: maximum of 1.00 AMA PRA Category 1 Credits™
Physicians ABIM MOC: maximum of 1.50 Medical Knowledge MOC points
CDK4/6 Inhibition in Breast Cancer: Expert Perspectives on Integrating Guideline Updates and Recent Advances Into Practice
Physicians: maximum of 1.50 AMA PRA Category 1 Credits™
Registered Nurses: 1.50 Nursing contact hours
Physician Assistants: maximum of 1.50 AAPA Category 1 CME credits
Pharmacists: 1.50 contact hours (0.15 CEUs)
Physicians ABIM MOC: maximum of 1.50 Medical Knowledge MOC points
Myeloma Masterclass: Applying the Latest Guidelines for Evidence-Based, Equitable Care
Physicians: maximum of 1.50 AMA PRA Category 1 Credits™
Registered Nurses: 1.50 Nursing contact hours
Physician Assistants: maximum of 1.50 AAPA Category 1 CME credits
Pharmacists: 1.50 contact hours (0.15 CEUs)
Physicians ABIM MOC: maximum of 1.50 Medical Knowledge MOC points
Complementing PARP Inhibition in Metastatic CRPC: Expert Insights and Strategies for Combining Therapeutic Approaches
Physicians: maximum of 1.50 AMA PRA Category 1 Credits™
Physicians ABIM MOC: maximum of 1.50 Medical Knowledge MOC points
Transforming Frontline Therapy in Hodgkin Lymphoma: Advancing Personalized Strategies for Optimal Outcomes
Physicians: maximum of 1.50 AMA PRA Category 1 Credits™
Physicians ABIM MOC: maximum of 1.50 Medical Knowledge MOC points
CELMoDs in Myeloma—What’s Here, What’s Next, and What’s on the Horizon
Physicians: maximum of 1.50 AMA PRA Category 1 Credits™
Physicians ABIM MOC: maximum of 1.50 Medical Knowledge MOC points
Redefining HCC Treatment in the Immunotherapy Era: Expert Insights, Multimodal Innovations, and Coordinated Care for Optimal Outcomes Across the Disease Continuum
Physicians: maximum of 1.00 AMA PRA Category 1 Credit™
Physicians ABIM MOC: maximum of 1.00 Medical Knowledge MOC point
Expert Perspectives on Updates and Advances in Individualizing CLL/SLL Therapy Across the Disease Course
Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Clinical Care Options, LLC
Supported by an independent medical education grant from AbbVie. Supported by educational grants from Bristol Myers Squibb and Lilly.
Mastering the Evolving Treatment Paradigm in SCLC: Expert Case Discussions to Aid Integration of Immunotherapy and Novel Targeted Therapies
Provided by Clinical Care Options, LLC
Supported by educational grants from Amgen, Daiichi Sankyo, Inc., Jazz Pharmaceuticals, Inc. and Merck Sharp & Dohme LLC.
Overcoming Endocrine Resistance in HR+/HER2- MBC: Tailoring Treatment for Patients With ESR1- and PI3K/AKT/PTEN-Altered Disease Post-ET Progression
Provided by Clinical Care Options, LLC
Supported by educational grants from AstraZeneca, Lilly and Stemline Therapeutics, Inc.
New Treatments on the Horizon: Cancer Conversations on Novel Mechanisms and Emerging Treatment Options in mCRPC
Provided by Clinical Care Options, LLC in partnership with ZERO Prostate Cancer
Supported by educational grants from Novartis Pharmaceuticals Corporation and Pfizer, Inc.
Challenging Treatment Paradigms in HER2-Low and HER2-Ultralow MBC: Experts Examine The Evidence to Guide Individualized Clinical Decisions
Provided by Clinical Care Options, LLC
Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.
Novel Therapeutic Approaches and Personalized Strategies for Managing Anemia in LR-MDS
Provided by Clinical Care Options, LLC
Supported by educational grants from Bristol Myers Squibb and Geron.
CDK4/6 Inhibition in Breast Cancer: Expert Perspectives on Integrating Guideline Updates and Recent Advances Into Practice
Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Clinical Care Options, LLC
Supported by educational grants from Lilly and Novartis.
Myeloma Masterclass: Applying the Latest Guidelines for Evidence-Based, Equitable Care
Provided by Clinical Care Options, LLC
Supported by educational grants from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC and Sanofi.
Complementing PARP Inhibition in Metastatic CRPC: Expert Insights and Strategies for Combining Therapeutic Approaches
Provided by Clinical Care Options, LLC
Supported by an education grant from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC and Pfizer Inc.
Transforming Frontline Therapy in Hodgkin Lymphoma: Advancing Personalized Strategies for Optimal Outcomes
Provided by Clinical Care Options, LLC
Supported by an educational grant from Bristol Myers Squibb.
CELMoDs in Myeloma—What’s Here, What’s Next, and What’s on the Horizon
Provided by Clinical Care Options, LLC
Supported by an educational grant from Bristol Myers Squibb.
Redefining HCC Treatment in the Immunotherapy Era: Expert Insights, Multimodal Innovations, and Coordinated Care for Optimal Outcomes Across the Disease Continuum
Provided by Clinical Care Options, LLC
Supported by educational grants from Eisai and Merck Sharp & Dohme LLC.
ASCO Disclaimer:
Not an official event of the 2025 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.
You are leaving the site. The new destination site may have a different terms of use and privacy policy.
We've updated our ad policy. Please review our policy here. Click 'Agree' to accept. If you do not accept, you cannot proceed to the site.
By clicking "Agree," you are agreeing to our Privacy Policy, Terms & Conditions and Ad Policy.